Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aegis Therapeutics
Aegis Therapeutics reports successful study results for Intravail in drug delivery
August 18th, 2006
Aegis Therapeutics announced the completion of its first human clinical study - a 10-patient, 3-way crossover trial designed to confirm the effectiveness of Intravail absorption enhancement agents in increasing intranasal bioavailability of peptide and protein drugs. The study, using a currently marketed drug of approximately 4000 Daltons in size, revealed an average systemic bioavailability of approximately 35% for the Intravail formulation compared to an average of 7% for the identical commercial formulation without Intravail. Aegis' Intravail provides exceptionally high and unmatched bioavailability performance via the intranasal and other mucosal membrane...
Source: Biotech Law Weekly (2006-08-18)
|
